| Dr Hormuz Irani, MD | |
|
5959 Truxtun Ave, Ste 100, Bakersfield, CA 93309-0435 | |
| (661) 638-0601 | |
| (661) 638-0605 |
| Full Name | Dr Hormuz Irani |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 46 Years |
| Location | 5959 Truxtun Ave, Bakersfield, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194708099 | NPI | - | NPPES |
| 00A411480 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | A41148 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventist Health Bakersfield | Bakersfield, CA | Hospital |
| Mercy Hospital | Bakersfield, CA | Hospital |
| Entity Name | Hormuz Irani Md Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962459677 PECOS PAC ID: 8224019773 Enrollment ID: O20040528001102 |
News Archive
IRIDEX Corporation, today announced the commencement of commercial shipment of the IQ 532 laser systems. The IQ 532 is a high-power, 532 nm, dual port multi-purpose laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma; and for use by otolaryngologists to correct certain types of conductive hearing loss.
According to a new study, smokers who receive multiple abnormal results using computed tomography (CT) to screen for lung cancer are more likely to quit, suggesting an opportunity for doctors to motivate smokers to quit smoking.
In a special report released August 23 in the journal Radiology, a team of researchers including Deborah Levine, MD, Director of Obstetric & Gynecologic ultrasound at Beth Israel Deaconess Medical Center and professor of radiology at Harvard Medical School, documented the brain abnormalities associated with congenital Zika in 45 confirmed and presumed cases from northeastern Brazil.
New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hormuz Irani, MD 5959 Truxtun Ave, Ste 100, Bakersfield, CA 93309-0435 Ph: (661) 638-0601 | Dr Hormuz Irani, MD 5959 Truxtun Ave, Ste 100, Bakersfield, CA 93309-0435 Ph: (661) 638-0601 |
News Archive
IRIDEX Corporation, today announced the commencement of commercial shipment of the IQ 532 laser systems. The IQ 532 is a high-power, 532 nm, dual port multi-purpose laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma; and for use by otolaryngologists to correct certain types of conductive hearing loss.
According to a new study, smokers who receive multiple abnormal results using computed tomography (CT) to screen for lung cancer are more likely to quit, suggesting an opportunity for doctors to motivate smokers to quit smoking.
In a special report released August 23 in the journal Radiology, a team of researchers including Deborah Levine, MD, Director of Obstetric & Gynecologic ultrasound at Beth Israel Deaconess Medical Center and professor of radiology at Harvard Medical School, documented the brain abnormalities associated with congenital Zika in 45 confirmed and presumed cases from northeastern Brazil.
New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.
› Verified 2 days ago
Dr. Alexandra Wertz Elias, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1700 Mount Vernon Ave, Bakersfield, CA 93306 Phone: 661-326-2000 | |
Mr. Jorge Enriquez, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2021 22nd St, Bakersfield, CA 93301 Phone: 661-864-7076 Fax: 661-864-7131 | |
Dr. Denise Portugal, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2021 22nd St, Bakersfield, CA 93301 Phone: 661-864-7076 Fax: 661-864-7131 | |
Dr. Oluwatosin Segun Fawibe, MD Surgery Medicare: Medicare Enrolled Practice Location: 3838 San Dimas St Ste B231, Bakersfield, CA 93301 Phone: 661-665-0505 Fax: 661-665-7844 | |
Aisha Waris Shaheen, MD, MHA Surgery Medicare: Accepting Medicare Assignments Practice Location: 1700 Mount Vernon Ave, Bakersfield, CA 93306 Phone: 661-326-2000 | |
Dr. Allan Lagdamen Capote, M.D. Surgery Medicare: May Accept Medicare Assignments Practice Location: 4901 Centennial Plaza Way, Bakersfield, CA 93312 Phone: 661-387-8333 Fax: 661-241-4052 | |
John Arthur Buxton, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2521 G St, Bakersfield, CA 93301 Phone: 661-327-2544 Fax: 661-327-0555 |